Solid tumor cells including prostate, colon [14], melanoma and breast cancer could secret GRP78 into tumor microenvironment and block the anti-angiogenic effect of bortezomib [15], suggesting GRP78 secreted by tumor cells plays an important role in the resistance to antiangiogenic therapy. Here, HSPA5 is linked to melanoma.